Last reviewed · How we verify
NCT06740539
Atrial Fibrillation with Heart Failure with Preserved Ejection Fraction: Treatment Strategies-Catheter Ablation Vs. Anti-Atrial Arrhythmia Drugs
NA trial testing Catheter ablation of atrial fibrillation in HFpEF - Heart Failure with Preserved Ejection Fraction in 304 participants. Not yet recruiting.
1 January 2027
Quick facts
| Lead sponsor | Shanghai Chest Hospital |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 304 |
| Start date | 16 December 2024 |
| Primary completion | 1 January 2027 |
| Estimated completion | 1 January 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- Catheter ablation of atrial fibrillation
Conditions studied
- HFpEF - Heart Failure with Preserved Ejection Fraction — all drugs for HFpEF - Heart Failure with Preserved Ejection Fraction →
- Atrial Fibrillation (AF) — all drugs for Atrial Fibrillation (AF) →
Sponsor
Shanghai Chest Hospital
Who can join
18 and older, any sex, with HFpEF - Heart Failure with Preserved Ejection Fraction or Atrial Fibrillation (AF). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A comparison of whether catheter ablation improves the prognosis (all-cause mortality and/or the composite endpoint of MACE) and reduces the recurrence rate of atrial fibrillation (AF) in patients with AF and heart failure with preserved ejection fraction (HFpEF), compared to anti-atrial arrhythmia drugs (AAD). This trial was randomly divided into two groups: the anti-AAD drug group and the catheter ablation group.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Transforming atrial fibrillation management by targeting comorbidities and reducing atrial fibrillation burden: the 10th AFNET/EHRA consensus conference.
Svennberg E, Merino JL, Andrade J, Anselmino M, et al · · 2025 · cited 5× · PMID 41392710 · DOI 10.1093/europace/euaf318
Verify or expand the search:
- PubMed search for NCT06740539
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Shanghai Chest Hospital trials
Trials by the same sponsor.
- NCT07515027 — Electroacupuncture Plus 5-HT3 Receptor Inhibitor for PONV Prevention in High-Risk Patients Undergoing Thoracoscopic Lung · NA · recruiting
- NCT07479628 — Neoadjuvant Adebrelimab Plus CRT for Locally Advanced Thymic Carcinoma · Phase 2 · not yet recruiting
- NCT07528066 — Downstaging and RATS After Neo-Chemo-IO: Impact on Surgical Outcomes in NSCLC · recruiting
- NCT07331727 — Epicardial Adipose Tissue-Targeted DApagliflozin for Reducing Electrical Remodeling in Atrial Fibrillation · NA · not yet recruiting
- NCT07320768 — Renal Denervation Combined With Pulsed Field Ablation to Prevent Blanking-Period Recurrence in Persistent Atrial Fibrill · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06740539 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Chest Hospital
- Last refreshed: 18 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06740539.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing